🇺🇸 FDA
Pipeline program

YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363

KT-US-982-5968

Phase 2 small_molecule active

Quick answer

YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363 for Solid and Hematological Malignancies is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Solid and Hematological Malignancies
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials